Cholangiocarcinoma
23066- Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements – 23066 TAS-120-205
STAR TRIAL = 2 WEEKS TO OPEN
- Phase – II
- Stage(s) – Locally advanced, metastatic, unresectable
- Line of Therapy – received at least one prior systemic gemcitabine and platinum-based regimen
- Investigational Drug – Futibatinib
- Drug Class – Kinase Inhibitor
- Mechanism of Action – inhibiting FGFR phosphorylation and, in turn, downstream signaling in FGFR-deregulated tumor cell lines
- Biomarker(s) – FGFR2 fusions or rearrangements